Difference between revisions of "Template:IHC of MMR"
Jump to navigation
Jump to search
(Noinclude) |
(Scoring) |
||
| Line 4: | Line 4: | ||
|author2= | |author2= | ||
}} | }} | ||
| − | </noinclude> | + | </noinclude>scoring is as follows:<ref>These cutoffs are used for both colorectal and endometrial cancers:<br>- {{cite journal|last1=Sarode|first1=Venetia R.|last2=Robinson|first2=Linda|title=Screening for Lynch Syndrome by Immunohistochemistry of Mismatch Repair Proteins: Significance of Indeterminate Result and Correlation With Mutational Studies|journal=Archives of Pathology & Laboratory Medicine|volume=143|issue=10|year=2019|pages=1225–1233|issn=0003-9985|doi=10.5858/arpa.2018-0201-OA}}<br>- {{cite journal| author=Sarode VR, Robinson L| title=Screening for Lynch Syndrome by Immunohistochemistry of Mismatch Repair Proteins: Significance of Indeterminate Result and Correlation With Mutational Studies. | journal=Arch Pathol Lab Med | year= 2019 | volume= 143 | issue= 10 | pages= 1225-1233 | pmid=30917047 | doi=10.5858/arpa.2018-0201-OA | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30917047 }}<br>- {{cite journal| author=Lee JHS, Li JJX, Chow C, Chan RCK, Kwan JSH, Lau TS | display-authors=etal| title=Long-Term Survival and Clinicopathological Implications of DNA Mismatch Repair Status in Endometrioid Endometrial Cancers in Hong Kong Chinese Women. | journal=Biomedicines | year= 2021 | volume= 9 | issue= 10 | pages= | pmid=34680502 | doi=10.3390/biomedicines9101385 | pmc=8533409 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34680502 }}</ref> |
<gallery mode=packed heights=190> | <gallery mode=packed heights=190> | ||
File:Immunohistochemistry of loss of expression of MLH-1.jpg|0% nuclear expression in tumor cell nuclei: '''Loss of expression''' (expression seen in stromal cells in image) | File:Immunohistochemistry of loss of expression of MLH-1.jpg|0% nuclear expression in tumor cell nuclei: '''Loss of expression''' (expression seen in stromal cells in image) | ||
Latest revision as of 18:34, 26 September 2022
Author:
Mikael Häggström, M.D. [note 1]
scoring is as follows:[1]
0% nuclear expression in tumor cell nuclei: Loss of expression (expression seen in stromal cells in image)
More than 0% but less than 10%: Indeterminate expression
10% or more: Retained expression
Contents
Notes
- ↑ For a full list of contributors, see article history. Creators of images are attributed at the image description pages, seen by clicking on the images. See Patholines:Authorship for details.
Main page
References
- ↑ These cutoffs are used for both colorectal and endometrial cancers:
- Sarode, Venetia R.; Robinson, Linda (2019). "Screening for Lynch Syndrome by Immunohistochemistry of Mismatch Repair Proteins: Significance of Indeterminate Result and Correlation With Mutational Studies ". Archives of Pathology & Laboratory Medicine 143 (10): 1225–1233. doi:. ISSN 0003-9985.
- Sarode VR, Robinson L (2019). "Screening for Lynch Syndrome by Immunohistochemistry of Mismatch Repair Proteins: Significance of Indeterminate Result and Correlation With Mutational Studies. ". Arch Pathol Lab Med 143 (10): 1225-1233. doi:. PMID 30917047. Archived from the original. .
- Lee JHS, Li JJX, Chow C, Chan RCK, Kwan JSH, Lau TS (2021). "Long-Term Survival and Clinicopathological Implications of DNA Mismatch Repair Status in Endometrioid Endometrial Cancers in Hong Kong Chinese Women. ". Biomedicines 9 (10). doi:. PMID 34680502. PMC: 8533409. Archived from the original. .
Image sources
